期刊文献+

CEF方案联合赫赛汀靶向治疗Ⅱ/Ⅲ期乳腺癌的临床效果观察 被引量:1

下载PDF
导出
摘要 目的观察CEF方案联合赫赛汀靶向治疗Ⅱ/Ⅲ期乳腺癌的临床效果。方法选择同期Ⅱ/Ⅲ期乳腺癌患者46例,以上患者经化疗后行乳腺根治手术治疗,其中对照组(n=28例)给予CEF方案化疗,观察组(n=18例)给予CEF方案联合赫赛汀靶向治疗,比较两组患者治疗2个周期后临床疗效及治疗期间不良反应情况。结果治疗2个周期后,观察组Karnofsky评分与临床疗效显著优于对照组(P<0.05),治疗期间两组出现的不良反应例数差异无统计学意义(P>0.05)。结论在Ⅱ/Ⅲ期乳腺癌患者的化疗过程中,应积极推广CEF方案联合赫赛汀靶向治疗。
作者 丁丽芳
出处 《中国医药指南》 2014年第16期132-133,共2页 Guide of China Medicine
  • 相关文献

参考文献7

二级参考文献35

  • 1王涛,江泽飞,宋三泰,刘晓晴,于静新,刘芳,闫敏.单药赫赛汀~治疗复发转移性乳腺癌[J].中华肿瘤杂志,2004,26(7):430-432. 被引量:25
  • 2夏恪迪,张馨木,张赢予.赫赛汀治疗HER-2过度表达晚期乳腺癌的疗效观察[J].中国厂矿医学,2007,20(1):25-26. 被引量:6
  • 3刘科,王国斌,程波,仇登波.GC方案与FEC方案新辅助化疗治疗乳腺癌患者的疗效比较[J].癌症,2007,26(4):427-430. 被引量:19
  • 4Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst, 1998, 90: 1361-1370.
  • 5陈强,叶韵斌,吴凡.HER-2单抗曲妥珠单克隆抗体耐药机制研究进展.[2009-11-20].http://reg.csco.org.on/reg2007/main/200706.pdf.
  • 6Antonio C, Wolff M, Elizabeth H, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 2007, 25:118 145.
  • 7Rakkhit R, Broglio K, Peintinger F, et al. Significant increased recurrence rates among breast cancer patients with HER-2- positive, T1a,b N0M0 tumors. San Antonio Breast Cancer Symposium Proceedings, San Antonio, Texas, USA, 2008. [2009-11-20]. http://www. abstracts2view, com/sabes/ search, php?.
  • 8Tovey SM, Marla S, Brown S, et al. Poor survival outcomes in HER-2 positive breast cancer patients with low grade, node negative turnouts: implications for trastuzumab therapy? San Antonio Breast Caneer Symposium Proceedings, San Antonio, Texas ,USA, 9008. [2009-11-20]. http://www, abstracts2view. corn/sahcs/search, php?.
  • 9Robert W, Benjamin O, Stephen B, et al. NCCN Clinical Practice Guidelines in Oncology^TM Breast Cancer V. 1. 2009. [2009-11-20]. http://www. necn. org.
  • 10Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab in patients with HER-2 positive locally advanced breast cancer: primary efficacy analysis of the NOAH triai. San Antonio Breast Cancer Symposium Proceedings, San Antonio, Texas, USA, 2008. [2009-11-20]. http://www. abstracts2view.com/sabcs/search, php?.

共引文献21

同被引文献8

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部